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Abstract: Significant benefits have been
gained with pre or peri-operative nutritional
support in surgical patients with malnutrition.
Recent studies have also shown that some
enteral formulas including certain nutrients
like glutamine could provide more benefit
than the standard formulas. In this
prospective-randomized study, the effects of
perioperative oral supplement with enteral
formulas containing glutamine in comparison
with a standard enteral formula in patients
who were operated on for GI malignancies
were examined. Thirty-two patients were
divided into two groups: the study group was
given oral supplement with an elemental diet
(Alitraq®) for 7 days preoperatively and 10
days postoperatively as 30-35% of total daily
requirement (standard hospital diet: 6570%), while the control group received a
polymeric formula (Ensure®) as the same
proportion of the daily intake for the same
duration. Freidman two-way ANOVA test,
Wilcoxon matched pairs signed ranks test and
Mann Whitney U test were used for statistical
analysis. One patient developed a minor
complication (wound infection) and another
had a major complication (anastomotic
disruption) in the control group, whereas no
surgical complications were encountered in
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Introduction
Malnutrition increases postoperative morbidity,
mortality and also hospitalization time in surgical patients
(1). This is an especially important problem for patients
with malignancies who undergo major operations (2, 3).
The mechanism is multifactorial: imparied oral food
intake, loss of appetite and tumor-related disorder in the
host metabolism. Patients with gastrointestinal (GI)
cancer have a particularly higher risk due to local effects
of the tumor (4, 5).
Clinically, significant benefits have been gained with
pre- or peri operative nutritional support in surgical
patients with malnutrition. Early studies on nutritional

the study group. The difference between the
two groups did not reach statistical
significance (p=0.21). There was no
significant difference between the groups
with respect to the intolerance of dietary
supplements. No nutritional indices showed
any difference between preoperative day 0
and preoperative day 8. Obvious declines were
observed in all plasma proteins immediately
following surgery. Prealbumin values in both
groups reached significantly high levels after
10-day postoperative nutritional support, but
albumin, prealbumin and transferrin levels
increased significantly only in the group on
the diet with glutamine during the
postoperative period. The results of the study
group in lymphocyte percentage and skin tests
were significantly better on postoperative day
11. The present study revealed that the
patients given enteral nutrition with
glutamine had improved immunologic
measurements,
and
developed
no
postoperative complications. In addition,
postoperative nutritional support seemed to
be more effective than preoperative feeding.
Key Words: Enteral nutrition, oral
supplement, glutamine, gastrointestinal
cancer.

manipulation usually used the parenteral route. In recent
years, the enteral route has gained in popularity. Enteral
access is easier than parenteral access, avoids catheter
infection and subsequent sepsis, which is one of the
serious complications of total parenteral nutrition (TPN),
and preserves gut immunity, integrity and motility. It has
been demonstrated that cancer patients given enteral
formulas have had improved immune function and
lowered surgical complication rates when compared with
patients who received no nutritional support (6). Some
recent studies have also shown that some enteral
formulas including certain nutrients like arginine,
glutamine and ω-3 fatty acids could provide more benefit
than the standard formulas (7-12).
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In this clinical study, we evaluated the
perioperative oral supplement with enteral
containing glutamine in comparison with a
enteral formula in patients who were operated
malignancies.

effect of
formulas
standard
on for GI

Materials and Methods
Thirty-two patients who were operated on for GI
(esophagus, stomach, colon, rectum) malignancies with
no distant metastasis in Surgical Department 4 of Ankara
Numune Teaching and Research Hospital between May
1995 and March 1997 were included in this prospectiverandomized study. The patient population was divided
into two groups: patients in the study group (SG) were

Table 1.

given oral supplement with an elemental diet containing
glutamine (Alitraq®-10 g glutamine/178 g, Ross
Laboratories, Columbus, Ohio) for 7 days preoperatively
and 10 days postoperatively as 30-35% of total daily
requirement (standard hospital diet: 65-70%), while
patients in the control group (CG) received a polymeric
formula (Ensure®, Ross Laboratories, Columbus, Ohio) as
the same proportion of the daily intake for the same
duration. Table 1 shows the compositions of the two
formulas used in the study.
All patients were evaluated according to the following
immunological parameters before commencing
nutritional support: white blood cell count (WBC: 410010900), total lymphocyte percentage (10.0-58.5%)
[ABBOTT CD-1700 autoanalyzer], and skin sensitivity

Composition of the standard and enriched diets.
Standard diet
(Ensure)

Enriched diet
(Alitraq)

% kcal
g / 1000 kcal
sources

14.0
42.0
sodium and calcium caseinate
soy protein isolate

21.0
52.5
hydrolyzed soy
and lactalbumin
11% whey protein
47% free amino acids
Glutamine (g/L): 14.2
arginine (g/L): 4.5
% BCAA protein: 18.5

% kcal
g / 1000 kcal
sources

54.5
133.6
non-hydrolyzed
corn starch
sucrose
lactose-free
gluten-free

66.0
165.0
85% maltodextrin
5% fructose
10% sucrose
lactose-free
gluten-free

% kcal
g / 1000 kcal
sources

31.5
33.6
corn oil
linoleic acid (g/L): 20
MCT (g/L): 0.07
ω-fatty acids (g/L): 0.46

13.0
15.5
safflower oil
linoleic acid (g/L): 6.6
MCT (g/L): 6.5
ω-fatty acids (g/L): 1.55

1.0
124 : 1
470
6.72

1.0
94 : 1
575
8.40

Protein

Carbohydrate

Fat

Caloric density
NPC : N *
Osmolality
Total nitrogen

(kcal / mL)
(mOsm / kg H20)
(g / L)

* NPC : N: Non-protein calorie : Nitrogen (g) ratio
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tests [Greer Derma PIK]. These tests were repeated on
the day before surgery and before starting oral intake in
the postoperative period. Finally all tests were done after
ten-day administration of nutritional supplement.
Nutritional support-related complications and surgical
complications were recorded.
Freidman two-way ANOVA test, Wilcoxon matched
pairs signed ranks test and Mann Whitney U test were
used for statistical analysis. A p value of less than 0.05
was considered significant.

Results
Thirty-two patients hospitalized for GI cancer without
distant metastasis during the study period were
evaluated. Each group consisted of 16 patients. The age
and sex characteristics of the groups were similar (mean
age: 52.94, S.E.: 13.09; 9 women and 7 men in the SG
vs mean age: 56.50, S.E.: 11.22; 8 women and 8 men in
the CG). Six patients in the CG and one patient in the SG
were excluded from the analysis because of an
unresectable tumor found in laparotomy. These seven
patients were not given enteral nutritional support
postoperatively. Of these patients, two patients in the CG
developed evisceration. One of them died of subsequent
sepsis. The tumor location and resectability rate in each
group are shown in Table 2.
One patient developed a minor complication (10%:
wound infection) and another had a major complication
Table 2.

(10%: anastomotic disruption, biliary peritonitis and
sepsis) in the CG, whereas no surgical complications were
encountered among the 15 patients in the SG. Overall
surgical complication rate was 20% in the CG. However,
the difference between two groups did not reach
statistical significance (p=0.21). There were no
statistically significant differences between the groups
with respect to the intolerance of dietary supplements in
the pre- and the postoperative periods (Table 3). In no
cases was it necessary to discontinue the enteral formula
due to side effects. The average postoperative stay in
hospital was similar for the two groups (mean: 18.3,
S.E.:5 for the CG vs mean: 15, S.E.:3 for the SG,
p=0.17).
No nutritional indices showed any difference between
preoperative day 0 and preoperative day 8. Obvious
declines were observed in all plasma proteins immediately
following surgery. Prealbumin values in both groups
reached significantly high levels after 10-day
postoperative nutritional support. However, albumin and
transferrin levels increased significantly only in the
enriched diet group during the postoperative period
(Table 4).
Immunological parameters of the groups in the pre(day-0 and day-8) and post operative (day 1 and day 11)
periods are shown in Table 5. There were significant
differences between the CG and the SG in lymphocyte
percentage and skin tests on postoperative day 11.

The tumor locations, surgical procedures and resectability rates.
CG (n=16)

SG (n=16)

Total (n=32)

7
2
7

1
8
1
6

1
15
3
13

3
2
2
2

3
5
1
1

6
7
3
3

6

1

7

62.5%

93.8%

78.1%

Tumour site
Esophagus
Stomach
Colon
Rectum

Surgical procedure
Total gastrectomy
Subtotal gastrectomy
Colectomy
Anterior resection of the rectum
Non-therapeutic laparotomy
due to unresectable tumor
Resectability rate*
*p=0.03
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Preoperative period
Nausea-vomiting
Total *

Postoperative period
Nausea-vomiting
Cramping-diarrhea
Total †

CG (n=16)
1

SG (n=16)
1

1
(6.3%)

1
(6.3%)

CG (n=10)
2

SG (n=15)
2
1

2
(20.0%)

3
(20.0%)

Table 3.

Intolerance of dietary supplements.

* p=0.31
† p=1.00

Table 4.

Nutritional indices.
Control Group

Study Group

Day

n

Mean (SD)

Day

n

Total protein (g/L)

Preop-0
Preop-8
Postop-1
Postop-11

16
16
10
10

67.67
70.87
57.10
67.80

Albumin (g/L)

Preop-0
Preop-8
Postop-1
Postop-11

16
16
10
10

37.93
42.47
32.40
36.60

Prealbumin (mg/dL)

Preop-0
Preop-8
Postop-1
Postop-11

16
16
10
10

Transferrin (mg/dL)

Preop-0
Preop-8
Postop-1
Postop-11

16
16
10
10

(4.03)
(4.31)
(6.47)
(7.04)

Preop-0
Preop-8
Postop-1
Postop-11

16
16
15
15

67.73
67.80
55.00
70.47

(4.91)
(5.41)
(5.00)
(3.48)

NS
NS
NS
NS

(4.77)
(5.22)
(4.72)
(6.69)

Preop-0
Preop-8
Postop-1
Postop-11 *

16
16
15
15

38.67
38.27
29.07
40.00

(3.92)
(3.95)
(9.70)
(3.59)

NS
p<0.05
NS
NS

18.09 (10.25)
17.50 ( 9.16)
13.03 ( 7.87)
21.52 (10.12)

Preop-0
Preop-8
Postop-1 †
Postop-11 ‡

16
16
15
15

18.97
19.67
9.78
25.35

(8.84)
(4.28)
(2.57)
(9.13)

NS
NS
NS
NS

Preop-0
Preop-8
Postop-1
Postop-11 ∫

16
16
15
15

(43.05)
(38.35)
(20.85)
(50.39)

NS
NS
p<0.05
NS

281.01
293.65
218.78
251.68

(66.30)
(63.11)
(47.89)
(79.34)

Mean (SD)

287.29
285.74
187.53
307.69

NS: Non-significant
* p<0.05 compared with postoperative day 1.
† p<0.05 compared with preoperative day 8.
‡ p<0.01 compared with postoperative day 1.
∫ p<0.05 compared with postoperative day 1.

Discussion
It has been shown that patients with malnutrition in
the preoperative period may stay in hospital for a long
time after major gastrointestinal surgery (1), and this
time can be reduced with nutritional support (7, 8). In
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patients with an intact gastrointestinal tract, the
preferred route for nutritional support is enteral access.
Several studies have revealed that enteral nutrition may
be a better way to improve nutritional parameters such
as prealbumin, retinol-binding protein and transferrin
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Table 5.

Immunologic measurements.
Control Group

Study Group

Day

n

Mean (SD)

Day

N

WBC (K/µL)

Preop-0
Preop-8
Postop-1
Postop-11

16
16
10
10

8.77
8.29
12.06
10.07

Lymphocyte %

Preop-0
Preop-8
Postop-1
Postop-11

16
16
10
10

Lymphocyte
3
count (/mm )

Preop-0
Preop-8
Postop-1
Postop-11

Candida albicans

Trichophyton rubrum

Mean (SD)

(3.12)
(3.20)
(6.90)
(4.90)

Preop-0
Preop-8
Postop-1
Postop-11

16
16
15
15

27.49
28.46
20.23
21.20

(7.92)
(7.88)
(8.38)
(7.91)

Preop-0
Preop-8
Postop-1
Postop-11

16
16
15
15

16
16
10
10

3823
3922
5766
5913

(2854)
(4671)
(4223)
(4701)

Preop-0
Preop-8
Postop-1
Postop-11

16
16
15
15

3471
3577
5286
5032

(2085)
(1963)
(3859)
(1791)

NS
NS
NS
NS

Preop-0
Preop-8
Postop-1
Postop-11

16
16
10
10

5.81
5.56
4.40
5.20

(0.91)
(1.21)
(0.84)
(1.39)

Preop-0
Preop-8 *
Postop-1
Postop-11 †

16
16
15
15

4.73
6.33
3.73
7.80

(0.70)
(1.39)
(0.70)
(2.48)

NS
NS
NS
p<0.05

Preop-0
Preop-8
Postop-1
Postop-11

16
16
10
10

5.56
5.69
4.30
5.20

(1.15)
(1.20)
(1.25)
(1.93)

Preop-0
Preop-8
Postop-1
Postop-11 ‡

16
16
15
15

4.73
6.53
3.60
8.00

(0.96)
(1.51)
(0.82)
(2.67)

NS
NS
NS
p<0.01

8.30
8.36
8.08
9.32

(2.23)
(1.97)
(2.90)
(6.65)

29.15 (9.05)
26.64 (7.42)
20.29 (9.70)
30.03 (11.06)

NS
NS
NS
NS
NS
NS
NS
p<0.05

Skin tests (mm)

NS: Non-significant
* p<0.05 compared with preoperative day-0.
† p<0.05 compared with preoperative day-0 and p<0.01 compared with postoperative day-1.
‡ p<0.01 compared with preoperative day-0 and postoperative day-1.

(13), and immunological measurements such as
monocyte
phagocytosis
ability
and
delayed
hypersensitivity test (7).

complications. In the same study, the gastrointestinal
complication rate among the patients fed a formula
enriched with ω-3 fatty acids was significantly lower.

Oral supplements and tube feeding formulas are
usually well tolerated by surgical patients when their
concentrations and administration rates are adjusted
carefully. Daly (8) reported that postoperative enteral
feeding via jejunostomy caused only mild and infrequent
gastrointestinal complications. The main side effect of
enteral nutrition in that series was long standing
diarrhea, while vomiting occurred in only 3 of 30
patients. Kenler and coworkers (12) investigated the
results of early enteral feeding in postsurgical cancer
patients recorded that 15 of 18 patients given a standard
diet via jejunostomy developed gastrointestinal

Not surprisingly, it has been observed that intolerance
to oral supplemental diet is less frequent than that to
total enteral nutrition. First of all, the specific
complications of feeding tubes were eliminated in oral
supplement studies. Furthermore, the hyperosmolality
related problems were diminished because oral food
intake was still allowed and the enteral formula was not
the sole ingredient in the intestinal lumen. In the present
study, intolerance to oral supplement was lower in
comparison with the results of the previous studies which
investigated the results of the total enteral nutrition. The
postoperative intolerance rates were similar in SG and
83
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CG. There were significant differences between pre- and
post operative intolerance rates in each group. These
differences probably originated from the surgical trauma.
However, these results do not mean that postoperative
enteral feeding is not well tolerated by the postsurgical
patients.
Many studies in the recent literature have shown that
some enteral formulas enriched with arginine-ω-3 fatty
acids and nucleotides (6-8, 10, 11) and glutamine (14,
15) are superior to standard diets for surgical patients.
Daly and coworkers (8) investigated the advantages of
enriched enteral formulas in patients with esophageal,
gastric or pancreatic cancer. In their enriched diet group,
only 10% of the patients developed major postoperative
complications. This was significantly lower than the 43%
complication rate of the standard diet group. The mean
hospital stay was also significantly shorter in the enriched
diet group. Senkal and colleagues (11) carried out a
similar prospective randomized study in surgical intensive
care patients. In the early postoperative period (1 to 5
days), there was no difference in postoperative
complication rates between the enriched formula group
and the standard enteral diet group. However, in the
subgroup of patients in whom complications occurred
after the fifth postoperative day, there was a statistically
significant reduction in the number of patients with late
complications in the enriched diet group. Braga and
colleagues (7) compared total parenteral, standard
enteral and enriched enteral nutrition groups in the early
postoperative period following major surgery for gastric
and pancreatic cancer patients. The mean hospitalization
times were similar in the two enteral groups, whereas the
parenteral nutrition group had a significantly longer
period in hospital. The sepsis score was significantly
lower in the enriched enteral group than in both the
standard enteral and total parenteral groups.
In contrast to the above mentioned series, which
investigated the results of total enteral nutrition,
McCarter and colleagues (16) found no significant
differences in postoperative complication rates or in
length of hospital stay between the patients receiving
standard or enriched diets as an oral supplement to the
standard hospital diet in the preoperative period. Use of
oral liquid supplements did not improve lymphocyte
proliferation or monocyte functions. A possible
explanation for the absence of any effect of preoperative
enriched supplement is that one week of preoperative
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enriched supplements might not be sufficient to enhance
immune function. They stated that it might not be
possible for preoperative supplements to improve an
immune system that was already functioning at a
relatively efficient level or the immunosupression
encountered in the immediate postoperative period might
be mediated by mechanisms that were not amenable to
correction with nutrients given before operation. In the
present study, immunologic measurements like
lymphocyte percentage and skin tests were significantly
better in the enriched supplemental diet group. In
addition, no postoperative complications were recorded
in this group. However, the differences in the
postoperative total or infectious complications rates
between the groups did not reach a significant level when
two patients in CG who developed evisceration after a
non-therapeutic laparotomy for unresectable tumors
were excluded from the analysis.
There is still no consensus on whether pre- or post
operative nutritional support is more useful. There is also
a limited number of studies which examine the results of
nutritional support given during both pre- and post
operative periods. In the present study, a sharp decline
was observed in skin test and plasma proteins on the
postoperative day 1 despite preoperative nutritional
support, as in several studies in which the patients were
not supported preoperatively (7, 10). There has been no
improvement in nutritional or immunologic parameters
from preoperative day 0 to preoperative day 8 during a
one-week nutritional support. However, lymphocyte
percentage, skin tests, albumin, prealbumin and
transferrin measurements significantly improved
following a 10-day postoperative administration of
enriched diet. In all four nutritional indices, postoperative
day 1 values were lower in the SG than in the CG, but
these indices were found to be higher in the SG at the end
of the postoperative nutritional support. Braga and
coworkers (9) found somewhat different results in
patients perioperatively fed with supplemented enteral
formulas.
Preoperative
supplementation
with
immunonutrients prevented early postoperative decrease
in phagocytosis and number of circulating lymphocytes,
which played a key role in the control of postoperative
infections.
Among certain nutrients in enriched formulas,
glutamine has some special features. Beyond this, it is the
most important nontoxic nitrogen transporter, it serves

N. Z. ERDEM, ‹. H. KULAÇO⁄LU, et al.

as a nontoxic carrier for ammonia, and it plays a role in
the regulation of acid-base balance. Glutamine may
regulate protein synthesis and provides precursors for
nucleotide and protein synthesis, and, most importantly,
is the major fuel for immune cells and enterocytes.
Shizuka (17) showed that intragastric administration of
glutamine increased small intestinal weight and mucosal
brush border enzyme acitivities, whereas intravenous
nutrition solution with glutamine at 20% of total amino
acids had no effect. Oral glutamine also decreases
translocation of enteric bacteria across the mucosal
barrier (18, 19), and improves the killing bacteria (18).
Demetriades and colleagues (20) reported that early
postoperative enteral nutrition enriched with glutamine
improved healing of experimental colonic anastomoses in
rats. Moreover, glutamine-enriched enteral feeding may
have an extra advantage in patients with GI cancer
because it enhances the tumoricidal effectiveness of
chemotherapeutic agents while reducing their morbidity
in a rat model (21).
Studies like the present one which have investigated
the nutritional and immunologic effects of glutamine and
other specific nutrients have generally had small numbers

of patients due to high cost. Sacks (22) has evaluated the
clinical trials and review articles in English (1970-1997)
which have examined the safety and efficacy of parenteral
and enteral glutamine supplementation in catabolic
patients. He has concluded that although glutamine has
shown promise in a select group of catabolic patients,
further studies are needed to define which patient
populations derive the greatest benefit from
supplemental glutamine. In our study, it was observed
that the patients given enriched enteral nutrition with
glutamine had improved immunologic measurements, and
developed no postoperative complications. In addition,
postoperative nutritional support seemed to be more
effective than preoperative feeding. We think additional
larger and multicenter studies will be of more benefit to
show the value of glutamine supplemented nutrition in
patients with GI cancer.

Correspondence author:
Hakan KULAÇO⁄LU
Bahçelievler, 1.cadde, 109/5
06490, Ankara-TURKEY
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